Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
50 studies found for:    "paraganglioma" OR "Paraganglioma"
Show Display Options
Rank Status Study
21 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
22 Recruiting Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Conditions: Neuroendocrine Tumor;   Paraganglioma;   Carcinoid Tumors;   Neuroblastoma
Intervention: Drug: DOTA-TOC PET/CT
23 Active, not recruiting Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Conditions: Carney Complex;   Chondrosarcoma;   Gastrointestinal Stromal Tumor;   Paraganglioma
Interventions: Drug: Linsitinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
24 Unknown  123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
25 Active, not recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Octreotide Acetate;   Drug: Everolimus;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
26 Active, not recruiting Stereotactic Body Radiotherapy for Spine Tumors
Conditions: Spinal Metastases;   Vertebral Metastases;   Benign Spinal Tumors;   Chordoma;   Meningioma;   Schwannoma;   Neurofibroma;   Paragangliomas;   Arteriovenous Malformations
Intervention: Radiation: stereotactic body radiotherapy
27 Active, not recruiting Stereotactic Body Radiotherapy for Head and Neck Tumors
Conditions: Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Salivary Gland Cancer;   Head and Neck Sarcoma;   Paraganglioma of Head and Neck;   Chordoma of Head and Neck;   Chondrosarcoma of Head and Neck;   Angiofibroma of Head and Neck
Interventions: Radiation: stereotactic body radiotherapy;   Radiation: Stereotactic body radiotherapy
28 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
29 Recruiting Cabozantinib for Malignant Pheochromocytoma
Condition: Neuroendocrine Tumors
Interventions: Drug: Cabozantinib;   Behavioral: Questionnaire
30 Recruiting Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Radiation: iobenguane I 131
31 Completed Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Condition: Chromaffin-tissue Derived Tumors
Intervention: Other: Scintigraphy in 123I-IBZM
32 Completed Diagnosis and Treatment of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
33 Completed Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
Condition: Pheochromocytoma
Intervention:
34 Completed Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Kidney Cancer;   Metastatic Cancer;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Procedure: conventional surgery
35 Terminated Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Conditions: Head and Neck Cancer;   Islet Cell Tumor;   Metastatic Cancer;   Pheochromocytoma
Interventions: Drug: octreotide acetate;   Radiation: yttrium Y 90 resin microspheres
36 Completed 131MIBG to Treat Malignant Pheochromocytoma
Condition: Pheochromocytoma
Interventions: Drug: [131]I-MIBG;   Drug: 6-[18F]Fluorodopamine;   Drug: [123]I-MIBG
37 Recruiting MIBG for Refractory Neuroblastoma and Pheochromocytoma
Conditions: Relapsed Neuroblastoma;   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG);   Drug: Potassium iodide solution;   Drug: G-CSF;   Procedure: hematopoietic stem cell infusion
38 Recruiting Phenoxybenzamine Versus Doxazosin in PCC Patients
Condition: Pheochromocytoma
Interventions: Drug: Phenoxybenzamine;   Drug: Doxazosin
39 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Childhood Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
40 Active, not recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Melanoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pheochromocytoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-50) Show next page of results    Last Page
Indicates status has not been verified in more than two years